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Purpose: Evaluate the effect of the marine lipid fraction of the New Zealand green-lipped
mussel (Perna canaliculus) PCSO-524 (Lyprinol/Omega XL), rich in omega-3 fatty acids,
on airway inflammation and the bronchoconstrictor response to eucapnic voluntary hyperpnea
(EVH) in asthmatics.
Methods: Twenty asthmatic subjects, with documented HIB, participated in a placebo
controlled double-blind randomized crossover trial. Subjects entered the study on their usual
diet and were then placed on 3 weeks of PCSO-524 or placebo supplementation, followed by
a 2 week washout period, before crossing over to the alternative diet. Pre- and post-eucapnic
voluntary hyperpnea (EVH) pulmonary function, fraction of exhaled nitric oxide (FENO),
asthma symptom scores, medication use, exhaled breath condensate (EBC) pH, cysteinyl leu-
kotrienes (cyst-LT), 8-isoprostane and urinary 9a, 11b-prostaglandin (PG)F2 and Clara (CC16)
protein concentrations were assessed at the beginning of the trial and at the end of each treat-
ment period.
Results: The PCSO-524 diet significantly reduced (p < 0.05) the maximum fall in post-EVH
FEV1 (8.4  3.2%) compared to usual (19.3  5.4%) and placebo diet (22.5  13.7%).
Pre- and post- EVH EBC cyst-LT and 8-isoprostane, and urinary 9a, 11b-PGF2 and CC16 concen-
trations were significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual
and placebo diet. EBC pH and asthma symptom scores were significantly improved
(p < 0.05) and rescue medication use significantly reduced (p < 0.05) on the PCSO-524 diet
compared to the usual and placebo diet.2 855 0753; fax: þ1 812 855 3193.
edu (T.D. Mickleborough).
3 Elsevier Ltd. All rights reserved.
13.04.010
Omega-3 fatty acids and asthma 1153Conclusion: PCSO-524 (Lyprinol/Omega XL) may have beneficial effects in HIB and asthma
by serving as a pro-resolving agonist and/or inflammatory antagonist.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Asthma is a multifaceted condition in which multiple
environmental and genetic influences can lead to several
clinical phenotypes such as exercise-induced bronchocon-
striction (EIB), which is a transient deterioration in lung
function following exercise,1 that can occur in patients with
asthma2 and elite athletes.3 The mechanisms responsible
for EIB likely involve multiple mechanistic pathways, how-
ever it is generally accepted that exercise or dry air hy-
perpnea play an important role as an initiating stimulus
through airway surface effects of water loss, which include
mucosal cooling, dehydration and epithelial disruption.1
This transient dehydration causes an increase in airway
surface liquid osmolality which activates histamine, neu-
ropeptides, and the release of leukotrienes and prosta-
glandins (arachidonic acid metabolites), from resident
airway cells, resulting in bronchial smooth muscle
contraction and subsequent airway narrowing.4
Although the treatment of EIB almost exclusively involves
pharmacotherapy, there is mounting evidence that nutri-
tional supplementation has potential to modify this condi-
tion.5 While the clinical data on the effect of fish oil
supplementation in asthma has been equivocal,6 supple-
menting the diet with fish oil rich in omega-3 (n-3) poly-
unsaturated fatty acids (PUFA), such as eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), in asthmatic
individuals7e9 and elite athletes with EIB10 has yielded
promising results. Two mechanisms of action underpinning
the novel anti-inflammatory bioactions of fish oil include the
ability of EPA to competewith arachidonic acid as a substrate
for cyclooxygenase (COX)-2 and 5-lipoxygenase (5-LO) en-
zymes and be converted to less inflammatory leukotrienes
and prostanoids,11 and to generate the potent anti-
inflammatory E-series resolvins.12 Less well-characterized
mechanisms include the capability of DHA to alter gene
transcription and translation via direct or indirect actions on
intracellular signaling pathways,13 and to produce the D-
series resolvins and protectins (neuroprotectin D1).12
While fish oil has been shown to attenuate airway
inflammation and the bronchoconstrictor response to ex-
ercise and dry gas hyperpnea,7,9,10 it is possible that
different forms of marine oils in the diet may have varying
effects of on these responses, since these oils contain a
variety of lipid mediators as well as different amount of n-3
PUFAs.14 PCSO-524 (Lyprinol/Omega XL) is a patented
extract of stabilized lipids from the New Zealand green-
lipped mussel (NZGLM), Perna canaliculus, combined with
olive oil and vitamin E.15 PCSO-524 is a multifarious
mixture of sterol esters, sterols, polar lipids, triglycerides
and free fatty acids (including EPA and DHA),16 and has
been shown to reduce pro-inflammatory leukotriene (LT)B4
in human monocytes,17 and to decrease levels of throm-
boxane B2, prostaglandin (PG) E2, and interleukin (IL) 1bwith similar potency to low dose n-3 PUFA supplementa-
tion.18 These findings support the potential for PCSO-524
to attenuate airway inflammation and bronchoconstriction
in asthma.
Daily supplementation with PCSO-524 in human asth-
matics has been shown to decrease daytime wheeze and
exhaled breath hydrogen peroxide concentration (a marker
of airway inflammation),19 and to suppress the develop-
ment of allergic inflammation and airway hyper-
responsiveness in a mouse model of ovalbumin (OVA)-
induced allergic airway disease.20
Therefore, the primary aim of this study was to evaluate
the effects of PCSO-524 supplementation on airway
inflammation and the bronchoconstrictor response to dry
air hyperpnea in individuals with asthma. We hypothesized
that PCSO-524 supplementation would significantly
attenuate airway inflammation and hyperpnea-induced
bronchoconstriction (HIB) in individuals with asthma.Methods
Subjects
Twenty subjects (12 males, 8 females, aged 22.6  2.1 yr,
height 168.8 þ 11.2 cm) with both physician-diagnosed
asthma and documented HIB were recruited from a popu-
lation of university students and the local community
(Fig. 1). All subjects had clinically treated mild to moderate
persistent asthma, with a resting forced expiratory volume
in 1-sec (FEV1) of >65% predicted (Table 1), and EIB as
demonstrated by a greater than 10% drop in FEV1 following
a eucapnic voluntary hyperventilation (EVH) challenge.21 A
group of non-asthmatic (control) subjects was not included
in the present study, as it has been shown that n-3 PUFA
supplementation does not alter pulmonary function or in-
flammatory mediator generation in this population.10
All subjects had a history of shortness of breath, chest
tightness, and intermittent wheezing following exercise,
which was relieved by bronchodilator therapy. No subjects
who volunteered for the study were currently taking any
maintenance medications (e.g., corticosteroids and leuko-
triene modifiers) for asthma. Short acting b2-agonists were
discontinued 12 h prior to testing. Caffeine/alcohol and
physical exercise was not permitted 8 h and 12 h respec-
tively prior to the EVH challenge. Subjects were also
excluded if they had a history of taking fish oil supplements
and regularly consumed more than one fish meal per week.
Subjects were asked not to eat more than one fish meal per
week during the course of the study. Subjects were
excluded if they were pregnant, had a history of hyperlip-
idemia, hypertension, diabetes, bleeding disorders, or
delayed clotting time. The study was approved by the
Indiana University Institutional Review Board for Human
Figure 1 CONSORT flow of participants through the study diagram.
Table 1 Pre-hyperpnea (baseline) pulmonary function.
Diet
PCSO-524 Usual Placebo
FVC (L) 4.34 þ 0.74 4.45 þ 0.82 4.29 þ 0.92
% predicted 92.4  5.2% 93.6  5.6% 90.1  6.1%
FEV1 (L) 3.60 þ 0.71 3.69 þ 0.72 3.59 þ 0.87
% predicted 93.8  7.9% 95.7  7.4% 92.2  6.5%
FEF25e75%(L/min) 3.58 þ 0.88 3.72  1.10 3.59  1.13
% predicted 97.1  7.6% 98.6  8.1% 97.9  8.4%
PEF (L) 7.43  1.31 7.52  1.65 7.61  1.91
% predicted 94.5  8.6% 95.6  9.1% 96.3  8.3%
Definition of abbreviations: FVC, forced vital capacity; FEV1, forced expiratory volume in 1-s; FEF25e75%, forced expiratory flow at
25e75% of FVC; PEF: peak expiratory flow. Values are mean  SD. There was no significant difference (p > 0.05) for any variables
between diets.
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Omega-3 fatty acids and asthma 1155Subjects, and written informed consent for all subjects was
obtained prior to participation in the study. The study was
registered as a phase 1 clinical trial with clinical trials.gov
(study # NCT01504646).
Study design
The study was conducted as a randomized, double-blind,
placebo-controlled crossover trial over 8 consecutive
weeks, with each subject serving as their own control.
Subjects were enrolled while on their usual diet. The order
of supplementation was randomly assigned with the use of
a computerized random number generator (http://www.
randomizer.org/form.htm). The randomization sequence
was created using a fixed random block size of two to
correspond to the two treatments (i.e. PCSO-524 and
placebo). Sealed capsule bottles labeled with one of two
material numbers were provided. Data collection and initial
data analysis was completed before the principle investi-
gator was informed which material number corresponded
to each treatment. The active and placebo capsules were
identical in appearance and taste so that subjects were not
aware of which treatment they received.
All subjects (n Z 20) underwent a 3 eweek run period
(usual diet; phase 1) preceding the start of the trial in
which asthma symptoms, bronchodilator use and peak flow
measurements were recorded, after which they were
randomly assigned to receive either 8 capsules per day of
PCSO-524 (Lypriniol/Omega-XL; Pharmalink Interna-
tional Ltd, Hong Kong) (n Z 10) containing approximately
72 mg EPA and 48 mg DHA (1 capsule contains 50 mg n-3
PUFAs and 100 mg olive oil or identical placebo (n Z 10,
placebo diet) capsules containing 150 mg of olive oil for 3
weeks (phase 2). Thereafter, they followed a 2-week
washout period (usual diet; phase 3) and then switched to
the alternative diet for the remaining 3 weeks (phase 4). All
subjects were asked to record bronchodilator use, symptom
scores and peak flow measurements during each dietary
treatment period.
A eucapnic voluntary hyperventilation (EVH) challenge
(surrogate for an exercise challenge test) was performed at
the beginning of the study and at the end of each treatment
period. Pulmonary function measurements were conducted
pre-EVH and post-EVH at 5, 10, 15, and 20 min. Exhaled
fraction of nitric oxide (FENO), a non-invasive measure of
airway inflammation, was measured pre-EVH and at 30 min
post-EVH. Exhaled breath condensate (EBC) was collected
pre-EVH and post-EVH from 0 to 10 min and analyzed for the
presence of the cysteinyl (Cyst)-leukotrienes (LTs) (marker
of airway inflammation22), 8-isoprostane (marker of oxida-
tive stress23 and airway pH. Urine samples were collected
pre-EVH and 60 min post-EVH for 9a, 11b-Prostaglandin F2
(sensitive marker of mast cell activation and airway inflam-
mation24), and pneumoprotein Clara cell (CC16; marker of
airway epithelial stress25) analysis. Food frequency ques-
tionnaires were administered at the beginning of each
testing session. Pre- and post-EVH pulmonary function and
FENO measurements were conducted at the end of the 2-
week washout period in order to verify that lung function
and exhaled nitric oxide values had returned to baseline
levels. Subjects were asked to record daily peak flow and
asthma symptom scores throughout the course of the study.Eucapnic voluntary hyperventilation
The EVH protocol required subjects to breathe compressed
dry air (<3 mg H2O.L
1 air and 21%O2, 5%CO2, balance N2)
at a predetermined rate of 85% of maximal voluntary
ventilation (estimated from 30  the volume of resting
FEV1) for 6 min. Gas flowed from a cylinder to a reservoir
bag through high-pressure tubing. From the reservoir bag
gas was directed to the subject through a tube connected
to a two way breathing valve and mouthpiece. Expired
gases passed through a flow sensor and ventilation was
measured and recorded as verification of respiration in-
tensity (Vmax 22 Metabolic Measurement Cart, Sensor-
Medics, Yorba Linda, CA).
Pulmonary function tests
Pulmonary function tests were conducted on all subjects
using a calibrated computerized pneumotachograph
spirometer (Vmax 22, SensorMedics, Yorba Linda, CA) ac-
cording to according to American Thoracic Society (ATS)
recommendations.26 The maximum percentage fall in FEV1
from the baseline (pre-EVH) value was calculated using the
following equation: (Pre-EVH FEV1 e lowest post-EVH
FEV1)/(Pre-EVH FEV1). In addition, the bronchoconstrictor
response to EVH was assessed as the area under the curve
of the percentage fall in post-EVH FEV1 plotted against time
for 20 min (AUC0e20), using trapezoidal integration.
Fraction of exhaled nitric oxide
Fraction of exhaled nitric oxide (FENO) was measured with
an online measurement of resting values using a restricted
exhaled breath protocol (NOA 280i Nitric Oxide Analyzer,
Accurate NO Breath Kit, Thermal Mass Flowmeter, NO
Analysis software Version 3.21, Sievers Instruments,
Boulder, CO). Measurements were conducted as outlined by
American Thoracic Society guidelines.27 Three exhalations
were performed with nose clips at each test with at least
30 s between exhalations.27 The procedure entailed
maximal inhalation to total lung capacity and immediate
exhalation against expiratory resistance for at least 6 s to
obtain a NO plateau lasting at least 3 s. Subjects were
instructed to maintain a flow rate of 50  10 mL/s as
monitored by a visual computer display.
Quantification of exhaled breath condensate
markers
EBC samples were collected with a specially designed
condensing chamber (ECoScreen, Jaeger, Hoechberg, Ger-
many) using ATS/ERS recommendations.28 The EBC protocol
required subjects to breathe normally, wearing nose clips,
through a mouthpiece connected to a non-rebreathing
valve, whereby exhaled breath entered a condenser sys-
tem. A temperature of 20 C inside the condensing
chamber, which was maintained throughout the collection
time, produced immediate sample freezing. Exhaled breath
was collected for 10 min prior to and intervals (0e10 min)
following the EVH challenge.
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diately following collection (Orion 2 star pH meter, Thermo
Scientific, Beverly, MA). It has been shown that pH mea-
surements in EBC collected by ECoScreen are repeatable
and reproducible.29
The remainder of the condensate was stored at 80 C
for later analysis of Cyst-LTs and 8-isoprostane using
enzyme immunoassay techniques (Cayman Chemicals, Ann
Arbor, MI) as previously discussed.9 Cross-reactivity of the
Cyst-LT antibody against an array of related compounds is:
LTC4 (100%), LTD4 (100%), LTE4 (67%), LTD5 (61%), LTC5
(54%), LTE5 (41%), N-acetyl-LTE4 (10.5%) and below 0.01%
for other primary eicosanoid metabolites. The intra- and
inter-assay coefficient of variation (CV) for the Cyst-LT
enzyme immunoassay kit is reported to be <10% respec-
tively. Cross-reactivity of the 8-isoprostane antibody
against an array of related compounds is: 8-isoprostane
(100%), 8-iso Prostaglandin F2a ethanolamide (100%), and
8-iso Prostaglandin F3a (20.6%).
Urinary 9a, 11b-prostaglandin (PG) F2 and clara cell
(CC16) quantification
Urine collection containers were provided to each subject
during each visit to the laboratory. The urine was subse-
quently pipetted into microfuge tubes and stored at 80 C
until analysis. Urine was assayed for 9a, 11b-PGF2 (Cayman
Chemicals, Ann Arbor, MI) and Clara Cell protein (CC16)
(BioVendor LLC, Karasek, Czech Republic) using enzyme
immunoassay techniques as discussed previously.9,25,30 The
9a, 11b-PGF2 antibody cross-reacts with 2,3 dinor-11b-
PGF2a (10%), 11b-13,14-dihydro-15-keto-PGF2a (0.5%) and
below 0.01% for all other primary eicosanoid metabolites.
The antibodies used in the CC16 ELISA are specific for
human Clara cell protein with no detectable cross reac-
tivity’s to the cytokines that may be present in human
serum. Inter- and intra-assay CV for the 9a, 11b-PGF2 and
CC16 assay is <15%, and 2.2% and 3.7% respectively. The
concentration of 9a, 11b-PGF2 and CC16 was adjusted for
creatinine concentration (Cayman Chemicals, Ann Arbor,
MI). The intra- and inter assay CV for creatinine is reported
to be 2.7% and 3.0% respectively.
Nutrient intake and compliance
Nutrient intake wasmonitored to ensure that dietary factors
that could potentially affect asthma or EIB did not change
through the course of the study. Nutrient data was collected
using the GSEL food frequency questionnaire developed by
the Nutrition Assessment Shared Resource (NASR) of Fred
Hutchinson Cancer Research Center. This questionnaire has
been shown to be valid and reliable in the collection of di-
etary data.31 Subjects completed the GSEL version of the
questionnaire at the first testing session and at the end of
each supplementation period. Analysis of GSEL for nutrient
intake was conducted by the Fred Hutchinson Cancer
Research Center. Nutrients of interest obtained from the
GSEL analysis included macronutrient composition, antioxi-
dants (a-tocopherol, b-carotene, lycopene, Vitamin C),
certain minerals (magnesium, sodium, zinc), and types of
dietary fatty acids (omega-3, total polyunsaturated fattyacids, saturated fatty acids). Adherence to the treatment
regimen was monitored by asking the subjects to document
the dose of capsules consumed daily and to return any un-
used capsules.32 For the purpose of the study a compliance of
90% was considered acceptable.
Symptoms, rescue b-agonist use and peak flow
measurements
Symptoms such as wheeze, shortness of breath, chest
tightness, and cough were recorded by each subject once
daily with the use of a logbook. The symptom severity
rating scale was defined as follows: 0: absent, no symp-
toms; 1: mild, symptom was minimally troublesome (not
sufficient to interfere with normal daily activity or sleep);
2: moderate, symptom was sufficiently troublesome to
interfere with normal daily activity or sleep; 3: severe,
symptom was so severe as to prevent normal activity and/
or sleep. All subjects were instructed to record each use of
their rescue medication throughout the study duration,
entering each medication use and the number of puffs used
per occasion. Subjects were asked to perform 3 peak flow
maneuvers at home in the morning and evening 2 weeks
prior to the start of study, and throughout the course of the
study. The subjects were provided with a peak flowmeter
(Piko-1, Ferraris, Louisville, CO) and a log to record the best
of 3 trials.
Data analysis
The primary analysis was on an intention-to-treat basis and
involved all subjects who were randomly assigned. Data
were analyzed using the SPSS version 20.0 statistical soft-
ware (SPSS Inc., Chicago, USA). Normality of data was
assessed using a KolmogoroveSmirnov test and Levene’s
test was used to check for homogeneity of variance be-
tween groups. A two-way repeated measures analysis of
variance (ANOVA) was used to analyze the data, with both
treatment and time as “within-subject” effects, whereas a
two-way analysis of variance was used to analyze “be-
tween-subject” effects. Mauchly’s test was conducted to
determine if sphericity was violated. If sphericity was
violated, the repeated measures ANOVA were corrected
using a Greenhouse-Geisser adjustment factor. Where a
significant F ratio was found (p < 0.05), a Fisher protected
least-square difference post-hoc test was used to detect
differences in group means (p < 0.05). The Wilcoxon signed
rank test was used to compare symptom scores and bron-
chodilator use during the trial. Data were analyzed for the
presence of carryover effects between treatments using a
2  2 ANOVA. Statistical significance was set at p < 0.05.
Data are expressed as mean  SD, and their 95% confidence
interval (CI).
Results
Subjects
Bronchodilator use (average number of doses/puffs per
day) was significantly reduced during the last 2 weeks of
Figure 2 The percentage change in FEV1 from pre- to post-
EVH across the three treatments. Reductions in post-EVH in
excess of 10% represent abnormal pulmonary function. Letters
a and b refer to comparisons by treatment within respective
time period. Different letters designate a significant difference
(p < 0.05).
Figure 3 Mean fraction of exhaled nitric oxide (FENO) con-
centration (ppb). # designates a statistical difference
(p < 0.05) from pre-EVH value within diet. * designates a sta-
tistical difference (p < 0.05) compared to respective time
point between diet.
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normal diet [9.8  2.5 puffs; p < 0.001; D (mean differ-
ence), 8.2  2.3 puffs; 95% CI, 6.3 to 8.8 puffs] and placebo
diet (8.5  2.5 puffs; p < 0.001; D, 6.9  2.8 puffs; 95% CI,
5.4 to 8.4 puffs). There was no significant difference
(p Z 0.456) in bronchodilator use between the normal and
placebo diet. A significant improvement in mean asthma
symptoms scores during the 3 week treatment period was
observed on the PCSO-524 diet (0.8  0.5) compared to
the normal diet (2.6  0.5; p < 0.001; D, 1.8  0.9; 95% CI,
1.3e2.3) and placebo diet (2.8  0.4; p < 0.001; D,
2.0  0.6; 95% CI, 1.6e2.3). No significant difference
(p Z 0.423) in mean asthma symptom scores was observed
between the normal and placebo diet. The combined mean
morning and evening peak flow was significantly increased
during the 3 week treatment period on the PCSO-524 diet
(386.3  22.8 L/min) compared to the normal diet
(370.4  23.6 L/min; pZ 0.001; D, 15.9  16.2 L/min; 95%
CI, 7.3 to 24.5 L/min) and placebo diet (364.5 þ 17.2 L/
min; p < 0.000; D, 21.8 þ 16.1 L/min; 95% CI, 13.2 to
30.4 L/min). There was no significant difference
(p Z 0.221) between the normal and placebo diet for the
combined mean morning and evening peak flow. A 2  2
ANOVA, used to test for the presence of carryover effects
between diets, indicated that none were present for all
measured variables (p < 0.05); this was further supported
by post-EVH pulmonary function and FENO values measured
at the end of the 2-week washout period returning to
baseline levels. In addition, no statistical difference
(p > 0.05) was observed between sex for all dependent
measures.
Pulmonary function
No significant difference was observed (p > 0.05) was
observed in baseline (pre-EVH) pulmonary function be-
tween groups (PCSO-524, placebo and usual diet) (Table
1). The percentage change in the pre-EVH to post-EVH
FEV1, as a consequence of diet, is shown in Fig. 2. The
maximum percentage drop in post-EVH FEV1 on the PCSO-
524 diet (8.4  3.2%), which is indicative of an attenu-
ated HIB response, was significantly less than the usual diet
(19.3 þ 5.4%; p < 0.001; D, 10.9  5.6%; 95% CI, 13.9
to 7.9%) and placebo diet (22.5  13.7; p < 0.001; D,
14.1  13.1%; 95% CI, 21.1 to 7.1%). Similar significant
(p < 0.05) changes a result of diet were observed for the
present drop in post-EVH FVC, FEF25e75% and PEF. The
bronchoconstrictor response to EVH as determined by the
AUC0-20 for FEV1 was significantly less on the PCSO-524
diet (112.3 þ 28.5) compared to the usual diet
(296.8  33.4; p < 0.001; D, 184.5  26.4; 95% CI,
124.7 to 234.3) and placebo diet (338.6  38.6;
p < 0.001, D, 226.3  31.2; 95% CI, 154.8 to 314.2). A
similar pattern was observed for the AUC0e20 for post-EVH
FVC, FEF25e75% and PEF.
Fraction of exhaled nitric oxide
Pre- and post-EVH FENO levels were significantly reduced on
the PCSO-524 diet (pre-EVH: 15.3 þ 10.7 ppb; post-EVH
(11.5 þ 8.2 ppb) compared to the usual diet (pre-EVH:33.6  33.7 ppb; p Z 0.046; D, 14.7  23.8 ppb; 95% CI,
0.04 to 30.4; post-EVH: 27.8  28.0 ppb; p Z 0.035; D,
16.3  22.7 ppb; 95% CI, 0.9e28.4 ppb) and placebo diet
(pre-EVH: 25.2  19.1 ppb; pZ 0.048; D, 13.9  19.1 ppb;
95% CI, 0.2 to 27.6; post-EVH: 22.9  17.4 ppb; p Z 0.049;
D, 11.4  17.3 ppb; 95% CI, 0.1e26.7 ppb) (Fig. 3).Exhaled breath condensate and urinary
inflammatory markers
The EBC pre-EVH pH was significantly higher on the PCSO-
524 diet (6.81  0.31) compared to the usual diet
1158 T.D. Mickleborough et al.(6.57 þ 0.29; pZ 0.016; D, 0.24 þ 0.35; 95% CI, 0.05e0.42)
and placebo diet (6.60  0.25; p Z 0.042; D, 0.21  0.38;
95% CI, 0.00845e0.41) (Fig. 4, Panel A). In addition, EBC pH
was significantly increased on the PCSO-524 diet at 5 min
(6.99  0.47) and 10 min (7.11  0.51) post-EVH compared
to 5 min (6.66  0.29; p Z 0.037; D, 0.33 þ 0.59; 95% CI,
0.184e0.534) and 10 min (6.57  0.41; p Z 0.003;
0.54  0.55; 95% CI, 0.250e0.945) post-EVH on the usual
diet and compared to 5 min (6.56  0.36; p Z 0.046; D,
0.43  0.62; 95% CI, 0.214e0.844) and 10 min (6.71  0.31;
p Z 0.015; D, 0.40  0.56; 95% CI, 0.134e0.938) post-EVH
on the placebo diet.
The mean pre- and post-EBC Cyst-LT concentration was
significantly reduced on the PCSO-524 diet (pre-EVH:
30.5  10.9 pg/ml; post-EVH: 41.9 þ 10.4 pg/ml) comparedFigure 4 Panel A. Mean exhaled breathe condensate (EBC) pH. # d
within diet. * designates a statistical difference (p < 0.05) compare
breathe condensate (EBC) cysteinyl-leukotriene concentration (p
compared to respective time point between diet. g designates a si
Panel C. Mean exhaled breathe condensate (EBC) 8-isoprostane co
(p < 0.05) compared to respective time point between diet. g des
within diet.to the usual (pre-EVH: 41.2  11.2 pg/ml; p < 0.001; D,
10.7  4.8 pg/ml; 95% CI, 7.5e13.6 pg/ml; post-EVH:
68.9  12.1 pg/ml; p < 0.001; D, 27.0  12.8 pg/ml; 95%
CI, 17.4e34.7 pg/ml) and placebo (pre-EVH: 42.1  2 pg/
ml; p < 0.001; D, 11.6 þ 4.5 pg/ml; 95% CI, 7.8 to 13.8;
post-EVH: 65.6  15.3 pg/ml; pZ 0.002; D, 23.7  14.9 pg/
ml; 95% CI, 11.1e33.9 pg/ml) diet (Fig. 4, Panel B).
Pre- and post-EVH EBC 8-isoprostane concentration was
significantly attenuated on the PCSO-524 diet (pre-EVH:
37.2  14.9 pg/ml; post-EVH: 53.8  13.3 pg/ml) compared
to the usual (pre-EVH: 46.4 þ 15.1 pg/ml; p Z 0.024; D,
9.2  13.4 pg/ml; 95% CI, 1.6e3.9 pg/ml; post-EVH:
61.1  15.4 pg/ml; p Z 0.043; D, 7.3  13.2 pg/ml; 95%
CI, 0.13e17.6 pg/ml) and placebo (pre-EVH:
49.3  15.5 pg/ml; p Z 0.001; D, 12.1  10.4 pg/ml; 95%esignates a statistical difference (p < 0.05) from pre-EVH value
d to respective time point between diet. Panel B. Mean exhaled
g mg1). *, # designates a statistical difference (p < 0.05)
gnificant difference (p < 0.05) from pre-EVH value within diet.
ncentration (pg mg1). *, # designates a statistical difference
ignates a significant difference (p < 0.05) from pre-EVH value
Omega-3 fatty acids and asthma 1159CI, 7.2e21.2 pg/ml; post-EVH: 66.0 þ 13.1 pg/ml;
pZ 0.040; D, 12.2  12.9 pg/ml; 95% CI, 0.63e20.5 pg/ml)
diet (Fig. 4, Panel C).
The mean urinary 9a, 11b PGF2 levels for pre- and post-
EVH was significantly mitigated on the PCSO-524 diet
(pre-EVH: 18.8  8.1 ng/mg creatinine; post-EVH:
31.0  15.4 ng/mg creatinine) compared to the usual
(pre-EVH: 23.6  11.9 ng/mg creatinine; p Z 0.036; D,
4.8 þ 8.3 ng/mg creatinine; 95% CI, 0.36e9.1 ng/mg
creatinine; post-EVH: 36.3  13.6 ng/mg creatinine;
p Z 0.041; D, 5.3  11.7 ng/mg creatinine; 95% CI,
0.2e11.5) and placebo (pre-EVH: 26.2  13.8 ng/mg
creatinine; p Z 0.008; D, 7.4  9.8 ng/mg creatinine; 95%
CI, 2.2e12.5 ng/mg creatinine; post-EVH: 41.2  20.1 ng/
mg creatinine; pZ 0.003; D, 10.2  11.6 ng/mg creatinine;
95% CI, 3.9e16.3 ng/mg creatinine) diet (Fig. 5, Panel A).
Mean urinary CC16 concentration pre- and post-EVH
decreased significantly on the PCSO-524 diet (pre-EVH:
0.054  0.047 ng/mmol creatinine; post-EVH:
0.69  0.49 ng/mmol creatinine) compared to the usual
(pre-EVH: 0.11  0.11 ng/mmol creatinine; p Z 0.048; D,
0.056 þ 0.100 ng/mmol creatinine; 95% CI,
0.0005e0.107 ng/mmol creatinine; post-EVH:
1.04  0.45 ng/mmol creatinine; p Z 0.017; D,
0.35  0.51 ng/mmol creatinine; 95% CI, 0.07e0.6) and
placebo (pre-EVH: 0.14  0.18 ng/mmol creatinine;
p Z 0.048; D, 0.086  0.16 ng/mmol creatinine; 95% CI,
0.0003 to 0.172; post-EVH: 0.98 þ 0.44 ng/mmol creatinine;
p Z 0.043; D, 0.29 þ 0.51 ng/mmol creatinine; 95% CI,
0.011e0.56) diet (Fig. 5, Panel B).
There was no significant difference (p > 0.05) between
the usual and placebo diets for pre-and post-EVH EBC Cyst-
LT and 8-isoprostane, and urinary 9a, 11b PGF2 and CC16
concentrations.Nutrient intake and compliance
Subject adherence to the treatment regimens were assured
by finding that pill counts at the end of each treatmentFigure 5 Panel A. Mean urinary 9a, 11b-prostaglandin F2 concen
difference (p < 0.05) compared to respective time point between
EVH value within diet. Panel B. Mean urinary CC16 concentration
(p < 0.05) compared to respective time point between diet. g des
within diet.period reflected that capsules were consumed on a regular
basis. Compliance as estimated from return-tablet count
was high (median, 99%). Though the usual diet was ex-
pected to vary between and among subjects, mean daily
nutrient intake of the subject’s diets did not differ signifi-
cantly (p < 0.05) between the treatment regimens.Discussion
This double-blind, randomized, crossover placebo-
controlled study has shown that a diet supplemented with
PCSO-524 (Lyprinol/OmegaXL) a patented extract of
stabilized lipids from the NZGLM, P. canaliculus, attenuates
airway inflammation, and the bronchoconstrictor response
to dry gas hyperpnea, and can reduce bronchodilator use
and asthma symptom scores in asthmatic subjects. The
PCSO-524 diet significantly reduced the severity of HIB as
measured by AUC0e20, and significantly reduced the
maximal fall in post-EVH FEV1 by approximately 57%. The
degree of protection provided by PCSO-524 on HIB in the
present study is similar in magnitude to previous reports
showing that 3 weeks of fish oil, rich in n-3 PUFA, reduced
the maximum fall in FEV1 post-exercise by almost 80%
10 and
64%7 in elite athletes and asthmatic subjects with EIB
respectively, and reduced the maximum fall in post-EVH
FEV1 by approximately 49% in asthmatic subjects with HIB.
9
In the present study the PCSO-524 diet significantly
reduced the pre-EVH FENO compared to the placebo and
usual diet, suggestive of amelioration in baseline airway
inflammation; this finding supports previous observations
that n-3 PUFA supplementation can moderate baseline
airway inflammation in asthmatics.9,33 In addition, the
present study demonstrated that the PCSO-524 diet can
reduce post-EVH FENO values compared to the usual and
placebo diets. It has been shown that FENO is an indirect
marker of asthmatic airway inflammation,34 and that a
relationship exists between FENO levels and EIB.
35
It has been shown that airway pH is a significant deter-
mining factor of expired FENO and airway inflammation,tration (ng mg mmol creatinine1). *, # designates a statistical
diet. g designates a significant difference (p < 0.05) from pre-
(ng mmol creatinine1). *, # designates a statistical difference
ignates a significant difference (p < 0.05) from pre-EVH value
1160 T.D. Mickleborough et al.and thus there may be a causal relationship between airway
acidification and airflow limitation in asthma.36 Airway pH
appears to be lower in asthmatics and correlates positively
with sputum eosinophilia, total nitrate/nitrite, and oxida-
tive stress.37 While airway acidity both accelerates human
eosinophil necrosis and can cause the conversion of
endogenous nitrate ðNO2 Þ to nitric oxide (NO), the acidic
airway breath condensate pH in asthma tends to normalize
with anti-inflammatory therapy,36 which supports the
findings of the present study, and our previous observa-
tion,9 that a diet supplemented with n-3 PUFA can alkalize
airway (EBC) pH in asthmatics.
Our finding that the PCSO-524 diet significantly
decreased EBC Cyst-LT concentration supports previous
studies that have shown that n-3 PUFA supplementation can
attenuate Cyst-LT levels in urine10 and induced sputum
following exercise,7 and in EBC following dry gas hyper-
pnea,9 compared to a usual (normal) diet in subjects with
EIB. Studies have shown a sustained increase in Cyst-LTs
and other bronchoconstrictve eicosanoids, such as PGD2,
in the airways after an exercise challenge,4,7,38 and these
markers have been shown to be elevated for up to 6 h after
an exercise challenge in asthmatic subjects with EIB.4 Eo-
sinophils, mast cells and basophils can directly synthesis
Cyst-LTs, which can cause tissue edema, stimulate airway
secretions, promote cell cycling and proliferation of airway
smooth muscle, and may directly increase eosinophilic
inflammation.22 It has been shown that in some patient
populations, the amount of eosinophilia in induced sputum
is correlated with EIB severity.39
The initial rate-limiting step in the formation of Cyst-LTs
and other eicosanoids is the release of arachidonic acid
from membrane phospholipids regulated by phospholipase
(PL) A2 enzymes.
40 It has been shown that secreted phos-
pholipase A2 group X (sPLA2-X) is elevated in induced
sputum cells of asthmatic patients with EIB,40 and
increased in the BAL fluid of asthmatics in association with
lung function and eicosanoid formation.41 It has been
shown that the major source of sPLA2-X is the airway
epithelium,41 and that the effects of exogenous sPLA2-X on
human eosinophils can rapidly initiate Cyst-LT formation in
eosinophils.42 These findings40 suggest that sPLA2-X may
serve as a significant regulator of airway eicosanoid for-
mation and that this enzyme is strongly implicated in the
pathophysiology of EIB/HIB.
The present study has shown that PCSO-524 can
significantly attenuate the increased urinary levels of CC16
observed prior to, and following, dry gas hyperpnea on the
placebo and control diet. CC16 is a low-molecular-weight
(16 kDa) protein, secreted in large amounts into the lumen
of the respiratory tract by nonciliated bronchiolar Clara
cells. Following its passage into the bloodstream across the
air-blood barrier, CC16 is rapidly eliminated by glomerular
filtration. In humans, CC16 in extrapulmonary fluid has
been used as indirect marker of lung epithelial cell dam-
age/dysfunction,25,30 and it has been suggested that CC16
may play a protective role in response to epithelial stress,
such as to protect the airway from dysfunction due to
dehydration of the epithelium43; most likely via inhibition
of PLA2 and the subsequent suppression of inflammatory
eicosanoids.25 Studies25,30 have shown that epithelial
stress, as shown by increases in urinary CC16 levels, occursduring exercise in vivo in elite swimmers, and following an
isocapnic hyperpnea challenge in trained and untrained
individuals, with and without EIB.
In the present study the PCSO-524 diet significantly
blunted the increase of urinary 9a, 11b-PGF2 prior to and
following the dry gas hyperpnea challenge, which confirms
previous findings of attenuated urinary 9a, 11b-PGF2 levels
following 3 weeks n-3 PUFA supplementation in elite ath-
letes with EIB10 and asthmatics with HIB.9 9a, 11b-PGF2, the
urinary metabolite of PGD2, is a sensitive marker of mast
cell activation in the airways and a potent bronchocon-
strictor,24 and has been shown to be increased after
allergen-induced bronchoconstriction,44 EIB,24 mannitol-
induced bronchoconstriction45 and hyperpnea-induced
bronchoconstriction.21
In the present study EBC 8-isoprostanne levels were
reduced prior to, and following, the dry gas hyperpnea
challenge on the PCSO-524 diet compared to the placebo
and control diet.
Oxidative damage to lipids (lipid peroxidation) leads to
the production of 8-isoprostane, an F2 isoprostane, formed
nonenzymatically by oxidation of arachidonic acid inde-
pendent of cyclooxygenase (COX) action, and considered a
reliable marker of oxidative stress because it is structurally
stable and are produced in vivo.46 Levels of 8-isoporstane in
EBC are increased in adults23 and children with asthma,47
and have been shown to be increased in EBC of asthmatic
patients with EIB, as well as correlated with the severity of
EIB.48
Although previous studies have shown that fish oil sup-
plementation provides a protective effect against EIB7,10
and HIB9 as a result of its anti-inflammatory properties,
the present study is the first to show that PCSO-524, a
different type of marine oil derived from the shellfish P.
canaliculus (NZGLM) is similarly effective as fish oil in
attenuating airway inflammation and HIB in asthmatic
subjects.9
While PCSO-524 has been shown to be effective in
treating osteoarthritis, rheumatoid arthritis, and inflam-
matory bowel disease,49 only a limited number of studies
have examined the efficacy of PCSO-524 in human
asthma19,50 and animal models of asthma.20 Emelyanov
et al.19 demonstrated in 46 patients with atopic asthma
that PCSO-524 (Lyprinol) [two capsules taken twice daily
for 8 weeks; each capsule containing 50 mg n-3 PUFA and
100 mg olive oil], compared to placebo, reduced daytime
wheeze and exhaled hydrogen peroxide (marker of airway
inflammation) and increased morning peak expiratory flow,
but did not improve night awakenings or reduce the use of
b2-agonists or forced expiratory volume in 1-sec (FEV1).
Recently, Lello et al.50 studied the use of PCSO-524
(Lyprinol) in 71 children with moderate chronic persistent
asthma taking regular inhaled corticosteroids (ICS). These
authors50 found that 16 weeks of PCSO-524 (Lyprinol)
supplementation improved the percentage of children
reporting slight to no problems with their asthma at 3
months of supplementation, and fewer mild and moderate
asthma exacerbations overall in the PCSO-524 (Lyprinol)
group. Wood et al.20 assessed the effects of 14 days of fish
oil and PCSO-524 (Lyprinol) supplementation on allergic
inflammation and lung function using a mouse model of
ovalbumin (OVA)-induced allergic airway disease (AAD).
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reduced eosinophil influx into the bronchoalveolar lavage
fluid, lung tissue and blood, decreased mucus hypersecre-
tion in the lung and attenuated airway hyperresponsiveness
(AHR). However, the effects seen on the PCSO-524
(Lyprinol) diet were not associated with changes in IgG1
and IgG2a, or the release of the cytokines IL-4, IL-5, IL-13
and IFN-g.
PCSO-524 is a mixture of the five main lipid classes
including sterol esters, triglycerides, free fatty acids, ste-
rols and polar lipids.51 PCSO-524 contains approximately
13% EPA, 21% DHA, 30% cholesterol and up to 91 fatty acid
components such as 5,9,12,15-octodecatretraenoic acid,
5,9,12,16-nondecatertraenoic acid, 7,11,14,17-eicosatetra
enoic acid, 5,9,12,15,18-heneicsapententaenoic acid,
myristic acid, palmitic acid, palmitoleic acid, stearic acid
and oleic acid.51 PCSO-524 has been shown to reduce the
pro-inflammatory LTB4 in human monocytes,
17 inhibit the
formation of 5-HETE (products from the lipoxygenase
pathway,52 attenuate the formation of LTB4 and 5-HETE
from human neutrophils,16 directly inhibit the COX-1 and
COX-2 enzymes,53 and to inhibit IL-1, IL-2, IL-6, TNF-a, IFN-
g synthesis from several LPS-stimulated isolated cell
preparations.54
In the present study the attenuation of airway inflam-
mation and subsequent improvement in pulmonary function
cannot be explained entirely by the EPA and DHA content of
PCSO-524, since the amount of EPA and DHA consumed
daily was only 72 mg and 48 mg respectively, which is
substantially lower than our previous studies examining the
effect of fish oil on EIB/HIB (3.2 g EPA/day and 2.0e2.2 g
DHA/day).7,9,10 Interestingly, Wood et al.20 have shown that
PCSO-524, but not fish oil, provides a protective effect
against eosinophilic inflammation, mucus production, TH2
cytokine responses in the lungs and airways, and airway
hyperresponsiveness, in a murine model of AAD. In addi-
tion, Whitehouse et al.52 showed that the lipid-rich oil of
PCSO-524 showed potent anti-inflammatory activity in rat
paw edema assays at a concentration two orders of
magnitude lower than fish oil containing abundant EPA,
while Tenikoff et al.55 has shown that PCSO-524 is more
effective than fish oil in reducing symptoms of
experimentally-induced inflammatory bowel disease, which
suggests that the potent anti-inflammatory effect of PCSO-
524 may not be due solely to the EPA and DHA content,
since in these two studies the n-3 PUFA content of PCSO-
524 compared to fish oil is significantly lower. Therefore,
it is possible that additional constituents of PCSO-524,
which may act synergistically with the n-3 PUFAs, may also
be partially responsible for its anti-inflammatory effects.
PCSO-524 is rich in anti-inflammatory polyphenols
(oleuropein and hydroxtyrosol) and oleic acid (18:1n-9),
which are postulated to reduce risk factors for heart dis-
ease, lower cancer mortality, and reduce inflammation.55 It
is also possible that the anti-oxidant component (D-a-
tocopherol) of PCSO-524 may be required to protect cell
membranes from an increased susceptibility of oxidation
which occurs with incorporation of n-3 PUFAs.56 Interest-
ingly, Wakimoto et al.57 have shown that furan fatty acids,
which are a minor component of PCSO-524, exhibit more
potent anti-inflammatory activity than EPA in a rat model of
adjuvant-induced arthritis, and may explain, at least inpart, why in the present study PCSO-524 was effective in
attenuating airway inflammation, given the very low dose
of EPA and DHA.
In conclusion, the present study has shown that a lipid
extract of NZGLM (PCSO-524) attenuates airway inflam-
mation and provides protection against HIB in asthmatic
subjects. This study supports data from previous
studies19,20 that PCSO-524 may have beneficial effects in
HIB/asthma, by serving as a pro-resolving agonist and/or
inflammatory antagonist. Further studies are required to
determine the minimum effective dose needed to atten-
uate HIB/asthma, and to determine the bioactive compo-
nents of PCSO-524 responsible for its anti-inflammatory
effect in asthmatic airways.
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